XOMA Selects Non-Infectious Anterior Scleritis as Next Indication in Gevokizumab Proof-of-Concept Program

[at noodls] – BERKELEY, Calif., Dec. 31, 2012 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced it has selected active non-infectious … more

View todays social media effects on XOMA

View the latest stocks trending across Twitter. Click to view dashboard

See who XOMA is hiring next, click here to view